NYSE:NVS - Novartis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $90.72 +0.75 (+0.83 %) (As of 02/20/2019 01:04 PM ET)Previous Close$89.97Today's Range$90.59 - $90.8552-Week Range$72.30 - $92.39Volume59,839 shsAverage Volume2.09 million shsMarket Capitalization$209.56 billionP/E Ratio17.83Dividend Yield2.12%Beta0.69 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland. Receive NVS News and Ratings via Email Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVS Previous Symbol CUSIPN/A Webwww.novartis.com Phone011-41-61-324-1111Debt Debt-to-Equity Ratio0.29 Current Ratio1.20 Quick Ratio0.97Price-To-Earnings Trailing P/E Ratio17.83 Forward P/E Ratio16.71 P/E Growth1.95 Sales & Book Value Annual Sales$51.90 billion Price / Sales4.04 Cash Flow$8.2248 per share Price / Cash Flow11.03 Book Value$34.07 per share Price / Book2.66Profitability EPS (Most Recent Fiscal Year)$5.09 Net Income$12.61 billion Net Margins24.30% Return on Equity15.66% Return on Assets8.43%Miscellaneous Employees125,161 Outstanding Shares2,310,000,000Market Cap$209.56 billion OptionableOptionable Novartis (NYSE:NVS) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS." How often does Novartis pay dividends? What is the dividend yield for Novartis? Novartis declared an annual dividend on Thursday, January 31st. Investors of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History. How will Novartis' stock buyback program work? Novartis declared that its board has initiated a share buyback program on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its shares are undervalued. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) posted its quarterly earnings data on Wednesday, January, 30th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.33 by $0.09. The business had revenue of $13.27 billion for the quarter, compared to the consensus estimate of $13.33 billion. Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm's revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 EPS. View Novartis' Earnings History. When is Novartis' next earnings date? Novartis is scheduled to release their next quarterly earnings announcement on Thursday, April 18th 2019. View Earnings Estimates for Novartis. What price target have analysts set for NVS? 15 brokerages have issued 1-year target prices for Novartis' shares. Their predictions range from $74.71 to $105.00. On average, they anticipate Novartis' stock price to reach $89.2467 in the next year. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? News stories about NVS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG). Who are Novartis' key executives? Novartis' management team includes the folowing people: Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)Mr. Harry Kirsch, Chief Financial Officer (Age 54)Mr. Steffen Lang, Global Head of Technical Operations (Age 52)Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51) Who are Novartis' major shareholders? Novartis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.50%), Bank of America Corp DE (0.39%), Fisher Asset Management LLC (0.33%), Boston Partners (0.31%), Mawer Investment Management Ltd. (0.21%) and Northern Trust Corp (0.18%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis. Which institutional investors are selling Novartis stock? NVS stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Millennium Management LLC, Schafer Cullen Capital Management Inc, Northern Trust Corp, Gabelli Funds LLC, Scout Investments Inc., Fort Washington Investment Advisors Inc. OH and Manning & Napier Group LLC. View Insider Buying and Selling for Novartis. Which institutional investors are buying Novartis stock? NVS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Mawer Investment Management Ltd., Boston Partners, Segall Bryant & Hamill LLC, Connor Clark & Lunn Investment Management Ltd., Financial Counselors Inc. and Fisher Asset Management LLC. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis. How do I buy shares of Novartis? Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novartis' stock price today? One share of NVS stock can currently be purchased for approximately $90.68. How big of a company is Novartis? Novartis has a market capitalization of $209.47 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe. What is Novartis' official website? The official website for Novartis is http://www.novartis.com. How can I contact Novartis? Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected] MarketBeat Community Rating for Novartis (NYSE NVS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 419 (Vote Outperform)Underperform Votes: 487 (Vote Underperform)Total Votes: 906MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?